JHS Svendgaard Laboratories Limited (JHS) AI Stock Analysis

• Market Cap: ₹1.06B
• Dividend Yield: N/A
• Average Volume (3M): 29.08K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.97
• Revenue Growth: 14.60%
• EPS Growth: -711.40%
• Country: IN
• Employees: 250
• Sector: Consumer Defensive
• Sector Strength: 67
• Industry: Household & Personal Products
• EPS (TTM): 0.12
• Shares Outstanding: 85,603,966
• 10 Day Avg. Volume: 64,768
• 30 Day Avg. Volume: 29,082
• PEG Ratio: N/A
• Price to Book (P/B): 0.00
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: ₹12.50
• Price Target Upside: 0.97% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 1

• Rating: 44 Neutral
• Price Target: ₹12.50 ▲(0.97% Upside)

JHS Svendgaard Laboratories Limited's stock score is primarily impacted by its financial challenges, including declining revenue and profitability issues, as well as liquidity concerns. Technical analysis also indicates bearish momentum. The negative valuation metrics further detract from the stock's attractiveness, leading to an overall low score.

JHS Svendgaard Laboratories Limited Business Overview & Revenue Model

Company Description

JHS Svendgaard Laboratories Limited (JHS) is an Indian company primarily engaged in the manufacturing of oral care products. The company specializes in producing a wide range of dental and oral hygiene products such as toothbrushes, toothpastes, and mouthwashes. JHS operates in the fast-moving consumer goods (FMCG) sector and serves both domestic and international markets, supplying products to various consumer retail brands and direct-to-consumer channels.

How the Company Makes Money

JHS Svendgaard Laboratories Limited generates revenue through the manufacturing and distribution of oral care products. The company's primary revenue streams include sales of private label products to major national and international retail chains, contract manufacturing for other consumer goods companies, and direct sales of its own branded products. JHS benefits from strategic partnerships with prominent retail brands, which help expand its market reach and distribution capabilities. Additionally, the company leverages economies of scale and manufacturing efficiencies to maintain competitive pricing and profitability in the oral care segment.

JHS Svendgaard Laboratories Limited Financial Statement Overview

Summary

JHS Svendgaard Laboratories Limited faces significant financial challenges. The income statement shows declining revenue and profitability issues, with negative net profit margins and consistent losses. The balance sheet is strong with low leverage, but cash flow analysis reveals liquidity struggles due to negative free cash flows and operational inefficiencies.

Income Statement

The income statement shows a declining trajectory in revenue, with a significant drop from 2020 to 2025. Gross profit margin improved to 33.66% in 2025, indicating better cost management. However, the company has been unprofitable since 2021, with a negative net profit margin of -21.47% in 2025. The EBIT and EBITDA margins are also negative, reflecting ongoing operational challenges.

Balance Sheet

The balance sheet shows a strong equity position with an equity ratio of 85.83% in 2025, suggesting financial stability. The debt-to-equity ratio remains low at 0.037, which indicates low financial leverage. However, the return on equity is negative due to consistent losses, highlighting profitability issues.

Cash Flow

Cash flow analysis reveals a negative free cash flow in recent years, with a significant deterioration in 2025. The operating cash flow to net income ratio indicates challenges in converting revenue into cash, with a negative ratio in 2025. Despite positive financing cash flow, the company struggles with liquidity due to poor operating performance.

Breakdown	Mar 2025	Mar 2024	Mar 2023	Mar 2022	Mar 2021
Income Statement
Total Revenue	919.97M	698.06M	840.82M	854.91M	1.00B
Gross Profit	309.55M	203.55M	165.45M	201.68M	264.03M
EBITDA	-39.92M	33.78M	-163.82M	85.45M	94.57M
Net Income	-197.44M	-40.58M	-175.17M	-40.52M	11.98M
Balance Sheet
Total Assets	2.01B	1.97B	2.28B	2.22B	2.28B
Cash, Cash Equivalents and Short-Term Investments	200.16M	101.40M	377.42M	80.19M	230.38M
Total Debt	64.58M	51.29M	155.09M	61.82M	70.11M
Total Liabilities	284.41M	271.70M	543.87M	269.46M	299.97M
Stockholders Equity	1.73B	1.70B	1.74B	1.86B	1.89B
Cash Flow
Free Cash Flow	-157.11M	-401.17M	89.43M	-158.75M	36.96M
Operating Cash Flow	-51.78M	-85.84M	232.86M	-91.36M	120.29M
Investing Cash Flow	-220.18M	-217.34M	96.77M	-46.97M	-22.25M
Financing Cash Flow	230.71M	21.74M	-9.00M	-16.72M	103.09M

JHS Svendgaard Laboratories Limited Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 12.38
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:JHS, the sentiment is Neutral. The current price of 12.38 is above the 20-day moving average (MA) of 12.33, below the 50-day MA of 12.83, and below the 200-day MA of 16.60, indicating a bearish trend. The MACD of -0.34 indicates Positive momentum. The RSI at 45.84 is Neutral, neither overbought nor oversold. The STOCH value of 53.11 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for IN:JHS.

JHS Svendgaard Laboratories Limited Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
GROBTEA	64 Neutral	₹1.28B	20.33		0.27%	9.17%	124.97%
NAGREEKEXP	51 Neutral	₹780.61M	24.76		―	-5.40%	-65.29%
Sector *	50 Neutral	AU$2.10B	-1.45	-9.83%	4.37%	4.08%	-50.27%
JHS	44 Neutral	₹1.06B	―		―	14.60%	-711.40%